Strategies to reduce SNAEs include preventing and reversing immunodeficiency, the modification of traditional risk factors, treatment of co-infections and addressing drivers of immune activation. A wide variety of agents are currently being examined for their potential effects in reducing immune activation and SNAEs (Table
2). However, the majority of studies that have been performed are small, are heterogeneous in terms of ART status and show conflicting findings. The majority of studies used markers of immune activation, in particular CD8 T cell activation as outcome measures. Some recent studies have also included sCD14 and D-dimer. However, randomized placebo-controlled trials that use clinical outcome measures are rare [
127].
Table 2
Potential strategies to reduce SNAEs
Preventing immunodeficiency
| Initiate ART prior to advanced immunodeficiency | |
Increasing CD4 T cell recovery
| | |
Cytokine therapy | Subcutaneous IL-2 | |
| Subcutaneous IL-7 | |
Modulating lymphoid tissue fibrosis | Pirfenidone | Human data pending |
| Angiotensin receptor antagonist | Human data pending |
| ACE inhibitor | Human data pending |
Managing co-morbidities
| Smoking cessation | |
| Optimise blood pressure, lipids and diabetic control | |
| ART switch | |
Reducing chronic antigen stimulation
| | |
Residual viraemia | Raltegravir intensification | |
| Maraviroc intensification | |
HBV and HCV co-infection | Hepatitis B and C treatment | |
CMV co-infection | Valganciclovir | |
HSV co-infection | Valacyclovir | |
Reducing inflammation
| Statins | |
| COX-2 inhibitors | |
| Aspirin | |
| Hydroxychloroquine & Chloroquine | |
| Leflunomide | |
| Prednisone | |
Reducing microbial translocation
| | |
Balancing microbiota | Prebiotic, probiotic and synbiotic | |
Reducing bacterial/endotoxin load | Rifaximin | Human data pending |
| Bovine colostrum | |
| Sevelamer | Human data pending |
Improving mucosal integrity | Lubiprostone | Human data pending |
Reducing inflammation in the gut | Mesalamine | Human data pending |
Optimizing cardiovascular risk factors
In the D.A.D study, patients who stopped smoking had about 30% reduction in the risk of CVD [
145]. Surprisingly, a reduction in mortality was not seen. This may be because patients ceased smoking after the diagnosis of a serious illness and succumb before the benefit of smoking cessation on mortality can be seen [
145]. In the Danish HIV cohort, previous smokers had a >1.5-fold reduction in mortality when compared with current smokers. In addition, though previous smokers have higher rates of AIDS-related deaths when compared with never smokers, the incidence of non-AIDS-related death was not different between previous and never smokers [
68]. These data suggest that smoking cessation alone would result in significant benefits and should be encouraged.
Modification of other cardiovascular risk factors e.g. treatment of hypertension, dyslipidaemia and optimal glycaemic control in diabetic patients is critical. Suggested target levels have been published [
146,
147]. Each 10 mmHg reduction in systolic blood pressure and each 38 mg/dL reduction in total cholesterol is associated with a 5 and 20% reduction in risk of CVD, respectively [
148]. However, in patients with known hypertension, diabetes or dyslipidaemia meeting indication for treatment, over 40% were not on treatment [
149]. Given that a significant proportion of SNAEs are cardiovascular events, more aggressive detection and management of cardiovascular risk factors will likely reduce SNAEs.
ART modification is a potential strategy to reduce cardiovascular risk [
150]. A recent review of switch studies have been published [
151]. Switching from stavudine to tenofovir was associated with a reduction in total cholesterol and triglycerides and an increase in limb fat [
152]. Switching from protease inhibitors to efavirenz or nevirapine was associated with reduction in total cholesterol [
153]. However, this switch is not possible in patients with non-nucleoside reverse transcriptase inhibitor resistance. Switching from lopinavir/ritonavir to atazanavir (both boosted with ritonavir 100 mg or unboosted) was associated with reduction of total cholesterol and triglycerides, though greater reductions were seen with unboosted atazanavir [
154‐
156]. Switching to atazanavir was also associated with a reduction in cardiovascular risk score [
157]. Though switching from lopinavir/ritonavir to raltegravir was associated with improvement in lipid profile [
158,
159], no change in endothelial function was detected [
160]. The importance of having fully active backbone antiretrovirals was highlighted in the SWITCHMRK study where patients switched to raltegravir had higher rates of virologic failure [
158].
Anti-inflammatory agents
Statins are 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors. Not only do statins reduce serum cholesterol [
180], they may also have anti-inflammatory properties [
181]. Statin use is associated with reduced monocyte activation (unpublished data McComsey et al), decline in CRP levels [
182] as well as reduced T cell activation [
183] in ART-treated and in untreated, HIV-infected patients [
184]. A retrospective observational study of ART-treated patients showed that statin use is associated with a 3-fold reduction in mortality [
185]. Though not statistically significant, a trend for reduction in SNAEs [
186] and mortality [
187] has also been seen in other retrospective observational studies.
Hydroxychloroquine (HCQ) and its analogue chloroquine (CQ) have immunomodulatory, anti-inflammatory and anti-HIV properties [
188‐
190]. In patients with uncontrolled viral replication, the use of CQ was associated with reduced CD8 T cell activation [
191] whereas the same effect was not seen with HCQ [
192]. However a non-randomized study of HCQ in 20 ART-treated patients showed decline in plasma LPS, IL-6 and reduced T cell and monocyte activation [
193]. Thus findings are inconclusive.
COX-2 inhibitors inhibit cyclooxygenase type 2, reducing Prostaglandin E2 production, thereby reducing activation of T cells through the cyclic adenosine monophosphate (cAMP) pathway [
194]. Studies on COX-2 inhibitors have been small and reduction in T cell activation tended to occur in viraemic patients [
195,
196]. However, it is important to bear in mind that COX-2 inhibitors are associated with increased cardiovascular risk, via a direct pharmacologic consequence of inhibition of COX-2 [
197]. Therefore assessing the utility of COX-2 inhibitors without using clinical outcome measures may be insufficient.
Aspirin is a cornerstone in the secondary prevention of vascular disease [
198]. In a pilot study, aspirin use was associated with reduced platelet activation, a decrease in sCD14 in monocytes and reductions in CD38 and HLA-DR on CD4 and CD8 T cells. However, there was no change in IL-6, D-dimer and CRP [
199]. An aspirin study with larger number of participants is in development with the AIDS Clinical Trials Group.
Leflunomide is an immunomodulatory agent that is used in the treatment of rheumatoid arthritis. The administration of leflunomide in untreated, HIV-infected patients for 28 days was associated with a decrease in CD8 T cell activation [
200].
The use of prednisone in patients with untreated chronic HIV infection was associated with less CD4 T cell depletion, a decline in CD4 T cell activation and stable HIV viral load [
201,
202]. Prednisone at 0.5 mg/kg/day in ART-treated patients was also associated with a reduction in CD8 T cell activation and TNF levels as well as a transient decrease in IL-6 [
203]. However, in another study using prednisone at 40 mg/day, no reduction in CD4 or CD8 T cell activation, plasma IL-6 or TNF levels was found [
204]. Furthermore, long-term prednisone use, especially at doses >7.5 mg/day is associated with significant adverse effects such as osteoporosis, impaired glucose tolerance, dyslipidaemia, weight gain, cataract formation and increased risk of infections [
205]. Even short courses have been associated with an increased risk of osteonecrosis in HIV-infected patients [
206].
Targeting microbial translocation
Given that HIV infection has been associated with depressed levels of beneficial gut microbiota and elevated levels of pathogenic microbiota [
207], a range of prebiotics (selectively fermented ingredients that changes the growth and/or activity of certain gut microflora, resulting in health benefits [
208]), probiotics (live microorganisms that when consumed, confer a health benefit [
209]) and synbiotics (combinations of pre and probiotics) are under investigation.
A prebiotic oligosaccharide mixture has been associated with improvement in microbiota composition and reduction in sCD14 in untreated HIV-infected patients [
210]. A retrospective cohort study on both ART-treated and untreated HIV-infected patients found that probiotic yogurt consumption was associated with a greater increase in CD4 T cell count even after adjustment for ART [
211]. A double-blind randomized placebo-controlled trial in 20 untreated HIV-infected patients found reductions in plasma bacterial DNA and IL-6 levels in patients receiving synbiotics [
212]. However, a synbiotic agent in ART-treated women found no change in microbial translocation nor immune activation status despite improvement in the levels of probiotic species [
213]. Therefore, more randomized controlled clinical trial data are needed to clarify the effects of pre and probiotics in reducing immune activation.
Bovine colostrum contains oligosaccharides, growth factors, immunoglobulins and antimicrobial peptides and has some activity in alleviating HIV-associated diarrhoea in single arm studies [
214‐
216]. However a randomized controlled trial on the addition of bovine colostrum to suppressive ART found no change in CD4 T cell count, markers of microbial translocation nor T cell activation [
167].
A number of new agents that target microbial translocation are under evaluation. Rifaximin is a minimally absorbed oral rifamycin antibiotic that has activity against both gram-positive and gram-negative enteric bacteria [
217]. It is effective in the treatment of hepatic encephalopathy, by reducing ammonia-producing enteric bacteria [
218,
219]. There are currently 3 clinical trials of rifaximin in HIV-infected patients (ClinicalTrials.gov identifier: NCT01654939, NCT01866826 and NCT01466595). Lubiprostone is a chloride channel activator that is used in the treatment of constipation [
220]. It has been found to enhance recovery of mucosal barrier function in ischaemic porcine colon [
221]. A pilot study of lubiprostone in ART treated, virologically suppressed patients with CD4 T cell count <350 cells/μL (NCT01839734) is currently recruiting. Sevelamer is a phosphate binder that is used in patients with end-stage renal failure [
222]. It can also bind to endotoxins and reduce CRP, IL-6 and sCD14 in patients on haemodialysis [
223,
224]. The trial in untreated, HIV-infected patients (NCT01543958) was completed in June 2013 and results are pending. Mesalamine (5-aminosalicylic acid) is an anti-inflammatory agent used in the management of inflammatory bowel disease [
225]. A trial using mesalamine in ART treated, virologically suppressed patients with CD4 T cell count <350 cells/μL (NCT01090102) is currently enrolling.